Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:SDZNY)

91.23 +0.19 (+0.21%)
Streaming Delayed Price Updated: 10:06 AM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about SDZNY

< Previous 1 2 Next >
News headline image
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars ↗
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
News headline image
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz reports second-quarter sales and half-year 2024 results
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
From Sandoz Group
Via GlobeNewswire
News headline image
3 Spinoff Stocks You Should Buy Now: July 2024 ↗
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early. 
Via InvestorPlace
News headline image
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
News headline image
Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
News headline image
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz reports first quarter 2024 sales
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab ↗
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost. 
Via Benzinga
Topics Intellectual Property
News headline image
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz receives FDA approval for first and only denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz announces nominations to the Board of Directors and leadership change
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
From Sandoz Group
Via GlobeNewswire
News headline image
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M ↗
Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchasers without admitting wrongdoing. Post-approval, litigation continues with... 
Via Benzinga
News headline image
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
From Sandoz Group
Via GlobeNewswire
News headline image
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today? ↗
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs. 
Via Benzinga
News headline image
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases ↗
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC:  
Via Benzinga
News headline image
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More ↗
Novartis AG (NYSE: NVS) reported  
Via Benzinga
Topics Earnings
News headline image
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. 
Via MarketBeat
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.